Copyright Reports & Markets. All rights reserved.

Global Afamelanotide Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Market Analysis by Type
    • 1.3.1 Overview: Global Afamelanotide Consumption Value by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 Subcutaneous Implants
    • 1.3.3 Injectables
    • 1.3.4 Transdermal Patches
    • 1.3.5 Oral Preparations
    • 1.3.6 Topical Preparations
  • 1.4 Market Analysis by Chemical Structure
    • 1.4.1 Overview: Global Afamelanotide Consumption Value by Chemical Structure: 2021 Versus 2025 Versus 2032
    • 1.4.2 Α-MSH Analogs
    • 1.4.3 Acetate Derivatives
    • 1.4.4 Free Peptide Derivatives
    • 1.4.5 Long-Acting Modified Derivatives
  • 1.5 Market Analysis by Pharmacological Effects
    • 1.5.1 Overview: Global Afamelanotide Consumption Value by Pharmacological Effects: 2021 Versus 2025 Versus 2032
    • 1.5.2 MC1R Selective Agonists
    • 1.5.3 Melanin Synthesis Stimulants
    • 1.5.4 Anti-Inflammatory Agents
    • 1.5.5 Neuroprotective Agents
  • 1.6 Market Analysis by Application
    • 1.6.1 Overview: Global Afamelanotide Consumption Value by Application: 2021 Versus 2025 Versus 2032
    • 1.6.2 Hematologic Disorders
    • 1.6.3 Skin Pigmentary Disorders
    • 1.6.4 Acute Diseases
    • 1.6.5 Autoimmune Diseases
    • 1.6.6 Neurodegenerative Diseases
  • 1.7 Global Afamelanotide Market Size & Forecast
    • 1.7.1 Global Afamelanotide Consumption Value (2021 & 2025 & 2032)
    • 1.7.2 Global Afamelanotide Sales Quantity (2021-2032)
    • 1.7.3 Global Afamelanotide Average Price (2021-2032)

2 Manufacturers Profiles

  • 2.1 Clinuvel Pharmaceuticals
    • 2.1.1 Clinuvel Pharmaceuticals Details
    • 2.1.2 Clinuvel Pharmaceuticals Major Business
    • 2.1.3 Clinuvel Pharmaceuticals Afamelanotide Product and Services
    • 2.1.4 Clinuvel Pharmaceuticals Afamelanotide Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 Clinuvel Pharmaceuticals Recent Developments/Updates
  • 2.2 Evonik Industries
    • 2.2.1 Evonik Industries Details
    • 2.2.2 Evonik Industries Major Business
    • 2.2.3 Evonik Industries Afamelanotide Product and Services
    • 2.2.4 Evonik Industries Afamelanotide Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 Evonik Industries Recent Developments/Updates
  • 2.3 Hangzhou Go Top Peptide Biotech
    • 2.3.1 Hangzhou Go Top Peptide Biotech Details
    • 2.3.2 Hangzhou Go Top Peptide Biotech Major Business
    • 2.3.3 Hangzhou Go Top Peptide Biotech Afamelanotide Product and Services
    • 2.3.4 Hangzhou Go Top Peptide Biotech Afamelanotide Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 Hangzhou Go Top Peptide Biotech Recent Developments/Updates
  • 2.4 Zhejiang Hengtengfu
    • 2.4.1 Zhejiang Hengtengfu Details
    • 2.4.2 Zhejiang Hengtengfu Major Business
    • 2.4.3 Zhejiang Hengtengfu Afamelanotide Product and Services
    • 2.4.4 Zhejiang Hengtengfu Afamelanotide Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.4.5 Zhejiang Hengtengfu Recent Developments/Updates
  • 2.5 Wepon
    • 2.5.1 Wepon Details
    • 2.5.2 Wepon Major Business
    • 2.5.3 Wepon Afamelanotide Product and Services
    • 2.5.4 Wepon Afamelanotide Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.5.5 Wepon Recent Developments/Updates

3 Competitive Environment: Afamelanotide by Manufacturer

  • 3.1 Global Afamelanotide Sales Quantity by Manufacturer (2021-2026)
  • 3.2 Global Afamelanotide Revenue by Manufacturer (2021-2026)
  • 3.3 Global Afamelanotide Average Price by Manufacturer (2021-2026)
  • 3.4 Market Share Analysis (2025)
    • 3.4.1 Producer Shipments of Afamelanotide by Manufacturer Revenue ($MM) and Market Share (%): 2025
    • 3.4.2 Top 3 Afamelanotide Manufacturer Market Share in 2025
    • 3.4.3 Top 6 Afamelanotide Manufacturer Market Share in 2025
  • 3.5 Afamelanotide Market: Overall Company Footprint Analysis
    • 3.5.1 Afamelanotide Market: Region Footprint
    • 3.5.2 Afamelanotide Market: Company Product Type Footprint
    • 3.5.3 Afamelanotide Market: Company Product Application Footprint
  • 3.6 New Market Entrants and Barriers to Market Entry
  • 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

  • 4.1 Global Afamelanotide Market Size by Region
    • 4.1.1 Global Afamelanotide Sales Quantity by Region (2021-2032)
    • 4.1.2 Global Afamelanotide Consumption Value by Region (2021-2032)
    • 4.1.3 Global Afamelanotide Average Price by Region (2021-2032)
  • 4.2 North America Afamelanotide Consumption Value (2021-2032)
  • 4.3 Europe Afamelanotide Consumption Value (2021-2032)
  • 4.4 Asia-Pacific Afamelanotide Consumption Value (2021-2032)
  • 4.5 South America Afamelanotide Consumption Value (2021-2032)
  • 4.6 Middle East & Africa Afamelanotide Consumption Value (2021-2032)

5 Market Segment by Type

  • 5.1 Global Afamelanotide Sales Quantity by Type (2021-2032)
  • 5.2 Global Afamelanotide Consumption Value by Type (2021-2032)
  • 5.3 Global Afamelanotide Average Price by Type (2021-2032)

6 Market Segment by Application

  • 6.1 Global Afamelanotide Sales Quantity by Application (2021-2032)
  • 6.2 Global Afamelanotide Consumption Value by Application (2021-2032)
  • 6.3 Global Afamelanotide Average Price by Application (2021-2032)

7 North America

  • 7.1 North America Afamelanotide Sales Quantity by Type (2021-2032)
  • 7.2 North America Afamelanotide Sales Quantity by Application (2021-2032)
  • 7.3 North America Afamelanotide Market Size by Country
    • 7.3.1 North America Afamelanotide Sales Quantity by Country (2021-2032)
    • 7.3.2 North America Afamelanotide Consumption Value by Country (2021-2032)
    • 7.3.3 United States Market Size and Forecast (2021-2032)
    • 7.3.4 Canada Market Size and Forecast (2021-2032)
    • 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 Europe

  • 8.1 Europe Afamelanotide Sales Quantity by Type (2021-2032)
  • 8.2 Europe Afamelanotide Sales Quantity by Application (2021-2032)
  • 8.3 Europe Afamelanotide Market Size by Country
    • 8.3.1 Europe Afamelanotide Sales Quantity by Country (2021-2032)
    • 8.3.2 Europe Afamelanotide Consumption Value by Country (2021-2032)
    • 8.3.3 Germany Market Size and Forecast (2021-2032)
    • 8.3.4 France Market Size and Forecast (2021-2032)
    • 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
    • 8.3.6 Russia Market Size and Forecast (2021-2032)
    • 8.3.7 Italy Market Size and Forecast (2021-2032)

9 Asia-Pacific

  • 9.1 Asia-Pacific Afamelanotide Sales Quantity by Type (2021-2032)
  • 9.2 Asia-Pacific Afamelanotide Sales Quantity by Application (2021-2032)
  • 9.3 Asia-Pacific Afamelanotide Market Size by Region
    • 9.3.1 Asia-Pacific Afamelanotide Sales Quantity by Region (2021-2032)
    • 9.3.2 Asia-Pacific Afamelanotide Consumption Value by Region (2021-2032)
    • 9.3.3 China Market Size and Forecast (2021-2032)
    • 9.3.4 Japan Market Size and Forecast (2021-2032)
    • 9.3.5 South Korea Market Size and Forecast (2021-2032)
    • 9.3.6 India Market Size and Forecast (2021-2032)
    • 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
    • 9.3.8 Australia Market Size and Forecast (2021-2032)

10 South America

  • 10.1 South America Afamelanotide Sales Quantity by Type (2021-2032)
  • 10.2 South America Afamelanotide Sales Quantity by Application (2021-2032)
  • 10.3 South America Afamelanotide Market Size by Country
    • 10.3.1 South America Afamelanotide Sales Quantity by Country (2021-2032)
    • 10.3.2 South America Afamelanotide Consumption Value by Country (2021-2032)
    • 10.3.3 Brazil Market Size and Forecast (2021-2032)
    • 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 Middle East & Africa

  • 11.1 Middle East & Africa Afamelanotide Sales Quantity by Type (2021-2032)
  • 11.2 Middle East & Africa Afamelanotide Sales Quantity by Application (2021-2032)
  • 11.3 Middle East & Africa Afamelanotide Market Size by Country
    • 11.3.1 Middle East & Africa Afamelanotide Sales Quantity by Country (2021-2032)
    • 11.3.2 Middle East & Africa Afamelanotide Consumption Value by Country (2021-2032)
    • 11.3.3 Turkey Market Size and Forecast (2021-2032)
    • 11.3.4 Egypt Market Size and Forecast (2021-2032)
    • 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
    • 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 Market Dynamics

  • 12.1 Afamelanotide Market Drivers
  • 12.2 Afamelanotide Market Restraints
  • 12.3 Afamelanotide Trends Analysis
  • 12.4 Porters Five Forces Analysis
    • 12.4.1 Threat of New Entrants
    • 12.4.2 Bargaining Power of Suppliers
    • 12.4.3 Bargaining Power of Buyers
    • 12.4.4 Threat of Substitutes
    • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

  • 13.1 Raw Material of Afamelanotide and Key Manufacturers
  • 13.2 Manufacturing Costs Percentage of Afamelanotide
  • 13.3 Afamelanotide Production Process
  • 13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

  • 14.1 Sales Channel
    • 14.1.1 Direct to End-User
    • 14.1.2 Distributors
  • 14.2 Afamelanotide Typical Distributors
  • 14.3 Afamelanotide Typical Customers

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Methodology
    • 16.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Afamelanotide market size was valued at US$ 69.76 million in 2025 and is forecast to a readjusted size of US$ 116 million by 2032 with a CAGR of 7.6% during review period.
    Afamelanotide is a synthetic peptide drug, an analog of alpha-melanocyte-stimulating hormone (α-MSH), used as a subcutaneous implant to prevent painful skin reactions from sun exposure in patients with the rare genetic disorder Erythropoietic Protoporphyria (EPP). It works by stimulating melanin (specifically eumelanin) production in the skin, which blocks light and reduces the severe pain, redness, and swelling caused by EPP. Administered as a small implant under the skin, it's released slowly over about two months.
    Global production of afanotide is projected to reach 3,000 vials by 2025, with an average price of US$22,600 per vial. Gross profit margins typically remain at a high level of 70% to 85%.
    Afamelanotide is a synthetic analog of melanocyte-stimulating hormone. Its upstream industry chain mainly consists of peptide raw materials and amino acid monomers, solid-phase synthesis resins and reagents, solvents, lyophilization excipients, sterile packaging materials, and bioanalytical testing services. The upstream focus lies in high-purity peptide synthesis and consistent quality control. Downstream demand is highly concentrated in rare disease and niche dermatology treatments, with its primary use in improving phototolerance for patients with erythropoietic protoporphyria. End users are mainly specialized hospitals, rare disease treatment centers, and reimbursement systems. Given the small and clearly defined patient population, downstream stakeholders prioritize clinical efficacy, safety, ease of administration, and long-term adherence. Payment is often supported by public insurance, special funds, or premium commercial insurance, resulting in relatively low price sensitivity but high requirements for clinical evidence. As real-world data accumulates, downstream applications are gradually expanding toward additional photosensitivity-related indications, while remaining focused on specialist channels and academic promotion.
    In terms of industry trends, Afamelanotide products are moving toward indication expansion, optimized delivery methods, and stronger real-world evidence generation. Key growth drivers include supportive orphan drug policies, incentives for rare disease development, and increasing advocacy from patient organizations. Major constraints include a limited patient base that caps market size, high development and regulatory costs, complex manufacturing barriers, and strong dependence on a single core product.
    This report is a detailed and comprehensive analysis for global Afamelanotide market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global Afamelanotide market size and forecasts, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
    Global Afamelanotide market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
    Global Afamelanotide market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
    Global Afamelanotide market shares of main players, shipments in revenue ($ Million), sales quantity (Units), and ASP (US$/Unit), 2021-2026
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Afamelanotide
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Afamelanotide market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Clinuvel Pharmaceuticals, Evonik Industries, Hangzhou Go Top Peptide Biotech, Zhejiang Hengtengfu, Wepon, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market Segmentation
    Afamelanotide market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    Subcutaneous Implants
    Injectables
    Transdermal Patches
    Oral Preparations
    Topical Preparations
    Market segment by Chemical Structure
    Α-MSH Analogs
    Acetate Derivatives
    Free Peptide Derivatives
    Long-Acting Modified Derivatives
    Market segment by Pharmacological Effects
    MC1R Selective Agonists
    Melanin Synthesis Stimulants
    Anti-Inflammatory Agents
    Neuroprotective Agents
    Market segment by Application
    Hematologic Disorders
    Skin Pigmentary Disorders
    Acute Diseases
    Autoimmune Diseases
    Neurodegenerative Diseases
    Major players covered
    Clinuvel Pharmaceuticals
    Evonik Industries
    Hangzhou Go Top Peptide Biotech
    Zhejiang Hengtengfu
    Wepon
    Market segment by region, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
    South America (Brazil, Argentina, Colombia, and Rest of South America)
    Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 15 chapters:
    Chapter 1, to describe Afamelanotide product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top manufacturers of Afamelanotide, with price, sales quantity, revenue, and global market share of Afamelanotide from 2021 to 2026.
    Chapter 3, the Afamelanotide competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
    Chapter 4, the Afamelanotide breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
    Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
    Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Afamelanotide market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
    Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
    Chapter 13, the key raw materials and key suppliers, and industry chain of Afamelanotide.
    Chapter 14 and 15, to describe Afamelanotide sales channel, distributors, customers, research findings and conclusion.

    Buy now